Predict your next investment

HEALTHCARE | Biotechnology

See what CB Insights has to offer


Series A | Alive

About Zhejiang Beta Pharma

Beta Pharma is a Chinese biotech company focused on the development of therapies for cancer and inflammatory diseases. In 2011, the company received Chinese FDA approval for its "Class One" new drug Icotinib, a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, for non-small cell lung cancer (NSCLC) in China. Icotinib is the first commercialized project in China's "Significant Innovative Drug Development" program. Beta Pharma is headquartered in Hangzhou, with its R&D center located in Beijing.

Zhejiang Beta Pharma Headquarter Location

589 Hongfeng Rd Yuhang

Hangzhou, Zhejiang , 311 100,



Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Zhejiang Beta Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Zhejiang Beta Pharma is included in 1 Expert Collection, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.